ISOMAR

Isomab is a UK-based biotechnology company focused on developing isoform-specific monoclonal antibodies to treat life-altering diseases. The company's lead program targets the VEGF-A165b isoform, a potent pro-angiogenic factor, to stimulate the growth of new blood vessels in patients with peripheral arterial disease (PAD). By specifically targeting this isoform, Isomab aims to restore blood flow and prevent limb loss in patients who have failed existing treatments. The company is also exploring the potential of its antibody platform in other indications, such as diabetic nephropathy and chronic kidney disease. Founded as a spin-out from the University of Nottingham and the University of Bristol, Isomab is advancing its pipeline toward clinical trials.